Kazia Therapeutics is pleased to make its March 2020 newsletter available to investors.

Our CEO, Dr James Garner sat down with Peter Switzer to discuss Kazia’s upcoming value-driving milestones in 2020 and the development of lead program, paxalisib, for Switzer Financial Group’s The CEO Masterclass series.

Our CEO, Dr James Garner was interviewed in BioWorld on the recent release of interim efficacy data from the phase II trial of GDC-0084 in glioblastoma as well as the overall GDC-0084 program.

Kazia is pleased to invite investors to view an archived copy of CEO, Dr James Garner’s address from the company’s 2019 AGM, together with questions and answers relating to the presentation.

Our CEO, Dr James Garner, sat down with CommSec’s Tom Piotrowski recently to discuss the company’s recent $4 million capital raising as well as key data readouts from Kazia’s clinical trials.

Our Chief Executive Officer, Dr James Garner, sat down with Karen Tan from Proactive Investors in Sydney to discuss the company’s recent achievements and upcoming milestones.

Kazia Therapeutics is pleased to make its September 2019 newsletter available to investors.

Kazia has been named as a winner in the 2019 Australian and New Zealand Leadership Forum (ANZLF) Trans-Tasman Innovation & Growth Awards.

Watch Dr James Garner's recent presentation at the Gold Coast Investment Showcase.

Kazia Therapeutics is pleased to make its June 2019 newsletter available to investors.

Our CEO, Dr James Garner sat down with Karen Tan from Proactive Investors in Sydney to discuss the release of new safety and tolerability data from the company’s phase IIa trial of GDC-0084 in newly-diagnosed brain cancer patients.

Kazia CEO James Garner's recent presentation at the recent Wholesale Investor Emergence event in Brisbane.

Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) has been selected to present data from the Phase I study of Cantrixil in ovarian cancer at the American Association for Cancer Research (AACR) 2019 Annual Meeting.  AACR is one of the top-tier academic conferences worldwide and will be held from 29 March to 3 April at the Georgia World Congress Center in Atlanta, Georgia, USA.

Kazia Therapeutics is pleased to make its February 2019 newsletter available to investors.

Dr Alan Olivero, who led the team at Genentech that developed GDC-0084, discusses what makes a good brain cancer drug.

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to invite investors to view an archived copy of CEO, Dr James Garner’s address from the company’s 2018 AGM, together with questions and answers relating to the presentation.

Kazia Therapeutics is pleased to make its November 2018 newsletter available.

The Australian oncology-focused biotech Kazia Therapeutics announced today that it will collaborate with world-leading treatment and research centre Dana-Farber Cancer Institute to investigate the use of Kazia’s potential new therapy for brain cancer, GDC-0084, in breast cancer that has spread to the brain.

The Australian phase 1 clinical trial of the drug Cantrixil for recurrent ovarian cancer could shape the next wave of clinical research into drugs targeting cancer stem cells, a peer-reviewed paper published in Expert Opinion on Orphan Drugs this month has found.

Kazia’s CEO Dr James Garner presented an overview of the company as a guest speaker at the 2018 Gold Coast Investment Showcase recently. Dr Garner’s presentation provides an excellent snapshot of the company at present and what makes its current therapies under development – Cantrixil for recurrent ovarian cancer and GDC-0084 for glioblastoma multiforme – different from existing treatment options and others in the clinic.